Phenotypeca starts important vaccine development project

As the latest step in our mission to make life-saving medicines more affordable to all, we have been awarded funding by the Bill & Melinda Gates Foundation to develop our baker’s yeast strains as an alternative platform to contribute to a reduction in the cost of vaccines for low- and middle-income countries.

Our founder, Keith Williams says: “This project is a monumental achievement and significant recognition for Phenotypeca as we continue to grow and improve our platform. As an organisation that shares our core values in fighting disease and inequity around the world, it is an honour to receive this funding from the Gates Foundation to help us improve the future of healthcare.”

This project is the latest in a series of successes using baker’s yeast to make spider silk, Covid-19 antigens, vaccine virus-like particles (VLPs) and several recombinant therapeutic proteins.

Follow us to stay up to date with our latest breakthroughs and upcoming announcements about a revolutionary project that will bring together the very best in science and technology.